Janux Therapeutics Inc (JANX) Price & Analysis

Compare

428 Followers

JANX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$22.48 - $71.71

Previous CloseN/A

Volume1.13M

Average Volume (3M)771.67K

Market Cap

$1.39B

Enterprise Value$676.84M

Total Cash (Recent Filing)$1.01B

Total Debt (Recent Filing)$22.61M

Price to Earnings (P/E)―

Beta2.00

Next Earnings

Aug 12, 2025

EPS Estimate

-0.46

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding59,175,156

10 Day Avg. Volume771,720

30 Day Avg. Volume771,666

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.49

Enterprise Value/Revenue72.50

Enterprise Value/Gross Profit76.65

Enterprise Value/Ebitda-6.04

Forecast

1Y Price Target

$81.00

Price Target Upside243.80% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say

Clinical Program DevelopmentJanux's expansion into 1L and 2L mCRPC markets represents a significant opportunity with a total market potential of approximately $10 billion in the U.S. alone.

Financial PositionWith a strong cash position of approximately $1 billion, Janux is well funded to achieve clinical proof of concept for the three new programs.

Preclinical And Novel ProgramsJanux raises the curtain on three preclinical programs, showcasing their ability to expand the company’s pipeline beyond ongoing clinical programs.

Bears Say

Regulatory And Development RisksThe combinations bring added development and regulatory risk and complexity.

Safety Data ConcernsJanux has not provided detailed safety data in the latest update, leaving some uncertainty.

Janux Therapeutics Inc News

CoreWeave initiated, Texas Instruments upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

25d ago

AMC

BYD

Janux Therapeutics initiated with an Outperform at Raymond James

Raymond James analyst Sean McCutcheon initiated coverage of Janux Therapeutics (JANX) with an Outperform rating and $65 price...

25d ago

JANX

Janux Therapeutics: Strategic Innovations and Robust Pipeline Drive Buy Rating

JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating today. Soumit...

8d ago

JANX

Optimistic Buy Rating for Janux Therapeutics Driven by Strategic Pipeline and Diversification

Leerink Partners analyst Jeffrey La Rosa has maintained their bullish stance on JANX stock, giving a Buy rating...

8d ago

JANX

Janux Therapeutics Inc: Strategic Advancements and Strong Positioning in Oncology Drive Buy Rating

In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Janux Therapeutics Inc,...

11d ago

JANX

Janux Therapeutics’ Strategic Expansion and Promising Pipeline Drive Buy Rating

Bank of America Securities analyst Alec Stranahan has maintained their bullish stance on JANX stock, giving a Buy...

11d ago

JANX

Janux Therapeutics Faces Trade Policy Challenges: Impact on Operations and Growth

Janux Therapeutics, Inc. (JANX) has disclosed a new risk, in the Capital Markets category. Janux Therapeutics, Inc. faces...

11d ago

JANX

Innovative Preclinical Programs and Strategic Tumor Activation Drive Buy Rating for Janux Therapeutics

William Blair analyst Matt Phipps has reiterated their bullish stance on JANX stock, giving a Buy rating on...

12d ago

JANX

Strategic Initiatives and Long-Term Potential Drive Buy Rating for Janux Therapeutics Inc.

Leerink Partners analyst Jeffrey La Rosa has maintained their bullish stance on JANX stock, giving a Buy rating...

15d ago

JANX

Janux Therapeutics Holds 2025 Annual Stockholders Meeting

Janux Therapeutics Inc ( ($JANX) ) has shared an update. On June 11, 2025, Janux Therapeutics, Inc. held...

2M ago

JANX

Promising Developments and Market Potential of Janux Therapeutics Inc.: A Focus on JANX007 and JANX008 Trials

JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on May...

3M ago

JANX

Janux appoints Janeen Doyle chief corporate, business development officer

Janux Therapeutics (JANX) announced the appointment of Janeen Doyle as chief corporate and business development officer. She joins...

3M ago

JANX

Janux Therapeutics Reports Increased Q1 Losses Amid R&D Expansion

Janux Therapeutics, Inc. ( ($JANX) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

JANX

Janux Therapeutics price target lowered to $36 from $41 at Scotiabank

Scotiabank lowered the firm’s price target on Janux Therapeutics (JANX) to $36 from $41 and keeps a Sector...

3M ago

JANX

JANX FAQ

What was Janux Therapeutics Inc’s price range in the past 12 months?

Janux Therapeutics Inc lowest stock price was $22.48 and its highest was $71.71 in the past 12 months.

What is Janux Therapeutics Inc’s market cap?

Janux Therapeutics Inc’s market cap is $1.39B.

When is Janux Therapeutics Inc’s upcoming earnings report date?

Janux Therapeutics Inc’s upcoming earnings report date is Aug 12, 2025 which is in 7 days.

How were Janux Therapeutics Inc’s earnings last quarter?

Janux Therapeutics Inc released its earnings results on May 08, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.382 by $0.002.

Is Janux Therapeutics Inc overvalued?

According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Janux Therapeutics Inc pay dividends?

Janux Therapeutics Inc does not currently pay dividends.

What is Janux Therapeutics Inc’s EPS estimate?

Janux Therapeutics Inc’s EPS estimate is -0.46.

How many shares outstanding does Janux Therapeutics Inc have?

Janux Therapeutics Inc has 59,175,156 shares outstanding.

What happened to Janux Therapeutics Inc’s price movement after its last earnings report?

Janux Therapeutics Inc reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.382. Following the earnings report the stock price went down -3.072%.

Which hedge fund is a major shareholder of Janux Therapeutics Inc?

Currently, no hedge funds are holding shares in JANX

Janux Therapeutics Inc Stock Smart Score

Outperform

Fundamentals

Return on Equity

-9.32%

Trailing 12-Months

Asset Growth

52.51%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Janux Therapeutics Inc

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Janux Therapeutics Inc (JANX) Earnings & Revenues

JANX Earnings Data >

JANX Stock 12 Month Forecast

Average Price Target

$81.00

▲(243.80%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","201":"$201","66.75":"$66.8","111.5":"$111.5","156.25":"$156.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$81.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,66.75,111.5,156.25,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.22,36.818461538461534,50.41692307692308,64.01538461538462,77.61384615384615,91.21230769230769,104.81076923076924,118.40923076923077,132.0076923076923,145.60615384615386,159.20461538461538,172.80307692307693,186.40153846153848,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.22,27.664615384615384,32.10923076923077,36.55384615384615,40.99846153846154,45.44307692307692,49.887692307692305,54.332307692307694,58.776923076923076,63.22153846153846,67.66615384615385,72.11076923076922,76.55538461538461,{"y":81,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.22,23.356923076923074,23.493846153846153,23.63076923076923,23.767692307692307,23.904615384615383,24.04153846153846,24.178461538461537,24.315384615384616,24.45230769230769,24.58923076923077,24.726153846153846,24.863076923076925,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.19,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.46,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >